Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × L19-IL2 immunocytokine × Clear all
NCT03705403 2025-01-30

IMMUNOSABR2

Maastricht University Medical Center

Phase 2 Terminated
88 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02735850 2017-05-23

ImmunoSABR

Maastricht Radiation Oncology

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡